✦ LIBER ✦

Vasoconstrictor therapy for patients with cirrhosis with ascites but without hepatorenal syndrome

✍ Scribed by Georgios N. Kalambokis; Epameinondas V. Tsianos

Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 47 KB
Volume: 48
Category: Article
ISSN: 0270-9139
DOI: 10.1002/hep.22247

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Terlipressin improves renal function in

Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome

✍ Aleksander Krag; Søren Møller; Jens H. Henriksen; Niels-Henrik Holstein-Rathlou; 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 200 KB 👁 1 views

Patients with advanced cirrhosis and ascites are characterized by circulatory dysfunction with splanchnic vasodilatation and renal vasoconstriction, which often lead to ascites. The vasoconstrictor terlipressin improves renal function in hepatorenal syndrome (HRS). The aim of this study was to evalu

Predictors of response to therapy with t

Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome

✍ André Nazar; Gustavo Henrique Pereira; Mónica Guevara; Marta Martín-Llahi; Marie 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 169 KB 👁 1 views

Terlipressin plus albumin is an effective treatment for type 1 hepatorenal syndrome (HRS), but approximately only half of the patients respond to this therapy. The aim of this study was to assess predictive factors of response to treatment with terlipressin and albumin in patients with type 1 HRS. T

Characterization of CD4+ T cells specifi

Characterization of CD4+ T cells specific for glutamic acid decarboxylase (GAD65) and proinsulin in a patient with stiff-person syndrome but without type 1 diabetes

✍ Arno Hänninen; Merja Soilu-Hänninen; Christiane S. Hampe; Angie Deptula; Kelly G 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 287 KB

A randomized trial of liposomal daunorub

A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome

✍ Jorge Cortes; Hagop Kantarjian; Maher Albitar; Deborah Thomas; Stefan Faderl; Ch 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 102 KB

## Abstract ## BACKGROUND Because angiogenesis may play a role in the pathogenesis of acute myeloid leukemia (AML) and high‐risk myelodysplastic syndrome (MDS), and thalidomide (Th) has shown significant anti‐angiogenic activity, this study was designed to investigate the potential role of Th in t